Stock ADVM ADVERUM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
10.43 USD +4.30% Intraday chart for Adverum Biotechnologies, Inc. +13.49% +38.55%
30/04 HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target MT
29/04 Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating MT

Business Summary

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Number of employees: 121

Sales per Business

USD in Million2022Weight2023Weight Delta
Gene Therapeutics
100.0 %
0 nan % 4 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 4 100.0 % -

Managers

Managers TitleAgeSince
Laurent Fischer CEO
 Chief Executive Officer 60 15/20/15
Linda Rubinstein DFI
 Director of Finance/CFO 58 12/22/12
Bill Tan CTO
 Chief Tech/Sci/R&D Officer - 01/21/01
Romuald Corbau CTO
 Chief Tech/Sci/R&D Officer 55 29/01
Peter Soparkar COO
 Chief Operating Officer 53 30/19/30
R. Ramelmeier CTO
 Chief Tech/Sci/R&D Officer 62 21/23/21
Anand Reddi HRO
 Human Resources Officer 42 -
Star Seyedkazemi PRN
 Corporate Officer/Principal 50 06/22/06
Heikki Jouttijärvi PRN
 Corporate Officer/Principal - 25/20/25
Dena House HRO
 Human Resources Officer - 01/19/01

Members of the board

Members of the board TitleAgeSince
Scott Michael Whitcup BRD
 Director/Board Member 64 16/20/16
Clarence Machado CHM
 Chairman 60 14/17/14
Laurent Fischer CEO
 Chief Executive Officer 60 15/20/15
Jim Scopa BRD
 Director/Board Member 65 01/19/01
C. Nicholson BRD
 Director/Board Member 68 03/11
Mark Lupher BRD
 Director/Board Member 53 01/19/01
Reed Tuckson BRD
 Director/Board Member 73 19/21/19
Dawn Svoronos BRD
 Director/Board Member 70 09/20/09
Rabia Ozden BRD
 Director/Board Member 56 17/22/17
Soo Hong BRD
 Director/Board Member 52 17/22/17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 20,754,915 20,267,441 ( 97.65 %) 0 97.65 %

Shareholders

NameEquities%Valuation
TCG Crossover Management LLC
9.676 %
2,008,340 9.676 % 28 M $
Logos Global Management LP
7.227 %
1,500,000 7.227 % 21 M $
Vivo Capital LLC
7.227 %
1,500,000 7.227 % 21 M $
BML Capital Management LLC
5.064 %
1,051,000 5.064 % 15 M $
Frazier Life Sciences Management LP
5.019 %
1,041,667 5.019 % 15 M $
Commodore Capital LP
4.818 %
1,000,000 4.818 % 14 M $
BML Capital Management LLC
4.014 %
833,117 4.014 % 12 M $
Fidelity Management & Research Co. LLC
2.951 %
612,428 2.951 % 9 M $
Bank of America, NA (Private Banking)
2.692 %
558,790 2.692 % 8 M $
Morgan Stanley Capital Services LLC
2.482 %
515,040 2.482 % 7 M $

Company contact information

Adverum Biotechnologies, Inc.

100 Cardinal Way

94063, Redwood City

+650 656 9323

http://www.adverum.com
address Adverum Biotechnologies, Inc.(ADVM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Adverum Biotechnologies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.43 USD
Average target price
35.33 USD
Spread / Average Target
+238.77%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADVERUM BIOTECHNOLOGIES, INC. Stock Adverum Biotechnologies, Inc.
+38.55% 216M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ADVM Stock
  4. Company Adverum Biotechnologies, Inc.